Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.

ABSTRACT:

Background

Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC.

Methods

This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, clinical stage IB to IIIA NSCLC. Patients received two doses of 200 mg pembrolizumab, surgery, standard adjuvant chemotherapy, followed by four doses adjuvant pembrolizumab. The primary objective of this study was to determine surgical feasibility rate, and secondary objectives are pathological response rate, treatment adverse events, efficacy data, and exploratory analysis of biomarkers.

Results

30 patients initiated perioperative pembrolizumab, and 25 completed tumor resection. At median follow-up of 59 months after sur

SUBMITTER: Wood C 

PROVIDER: S-EPMC11795402 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature